Wednesday, May 19, 2021

Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia

›
PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stag...
Friday, May 14, 2021

Reverse phase protein array reveals correlation of retinoic acid metabolism with cardiomyopathy in Friedreich’s ataxia

›
Jill S. Napierala, Kimal Rajapakshe, Amanda Clark, Yu-Yun Chen, Shixia Huang, Clementina Mesaros, Peining Xu, Ian A. Blair, Lauren A. Hauser...
Thursday, May 13, 2021

Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress

›
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs uti...

Toxicity concerns send Larimar down

›
Evaluate Vantage. May 12, 2021.  Slightly further behind is Larimar, which yesterday reported phase 1 results with its candidate CTI-1601. ...

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

›
BALA CYNWYD, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology com...
Monday, May 10, 2021

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

›
BALA CYNWYD, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology com...
Friday, May 7, 2021

Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

›
May 06, 2021, Source: Reata Pharmaceuticals, Inc.  Data from the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone i...

Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia

›
Johnson J, Mercado-Ayón E, Clark E, Lynch D, Lin H.; Pharmacol Res Perspect. 2021 May;9(3):e00755. doi: 10.1002/prp2.755. PMID: 33951329. T...
Thursday, May 6, 2021

Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort

›
Rummey C, Flynn JM, Corben LA, Delatycki MB, Wilmot G, Subramony SH, Bushara K, Duquette A, Gomez CM, Hoyle JC, Roxburgh R, Seeberger L, Yoo...
Monday, May 3, 2021

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)

›
Fernando de Andrés-Nogales, Encarnación Cruz, Miguel Ángel Calleja, Olga Delgado, Maria Queralt Gorgas, Jaime Espín, Jorge Mestre-Ferrándiz,...